Click on the tabs above by breast cancer type to view active trials.
Protocol # | Sponsor | Protocol Title |
---|---|---|
NCT02132949 | Hoffmann-La Roche WO29217 | A Study Evaluating Perjeta (Pertuzumab) Combined With Herceptin (Trastuzumab) and Standard Anthracycline-based Chemotherapy in Patients With HER2-positive Locally Advanced, Inflammatory, or Early-Stage Breast Cancer. |
Protocol # | Sponsor | Protocol Title |
---|---|---|
NCT02132949 | Hoffmann-La Roche WO29217 | A Multi-Center, Multi-National, Phase II Study to Evaluate Pertuzumab in Combination With Trastuzumab and Standard Neoadjuvant Anthracycline-based Chemotherapy in Patients with HER2-Positive, Locally Advanced, Inflammatory, or Early-Stage Breast Cancer |
NCT02132949 | MacroGenics CP-MGAH22-04 | A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Two Prior Anti-HER2 Therapies and Require Systemic Treatment |
Protocol # | Sponsor | Protocol Title |
---|---|---|
NCT02340221 | Hoffmann-La Roche GO29058, 2014-003185-25 | A Phase III, Double-Blind, Placebo Controlled, Randomized Study of Taselisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy (SANDPIPER) |
NCT02278120 | Novartis Pharmaceuticals CLEE011E2301 | A Phase III Randomized, Double-Blind, Placebo-controlled Study of LEE011 or Placebo in Combination With Tamoxifen and Goserelin or a Non-Steroidal Aromatase Inhibitor (NSAI) and Goserelin for the Treatment of Premenopausal Women with Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer |
NCT02000622 | AstraZeneca D0819C00003, 2013-005137-20 | A Phase III, Open Label, Randomized, Controlled, Multi-center Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutations. (OlympiAD) |
Protocol # | Sponsor | Protocol Title |
---|---|---|
NCT02425891 | Hoffmann-La Roche WO29522, 2014-005490-37 | A Study of MPDL3280A in Combination with Nab-Paclitaxel Compared with Placebo With Nab-Paclitaxel for Patients with Previously Untreated Metastatic Triple Negative Breast Cancer |
NCT02340221 | Hoffmann-La Roche GO29058, 2014-003185-25 | SANDPIPER Study: A Study Of Taselisib + Fulvestrant Versus Placebo + Fulvestrant In Patients With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy |
NCT02000622 | AstraZeneca D0819C00003, 2013-005137-20 | A Phase III, Open Label, Randomized, Controlled, Multi-center Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. (OlympiAD) |
NCT02278120 | Novartis Pharmaceuticals CLEE011E2301 | A Phase III Randomized, Double-blind, Placebo-controlled Study of LEE011 or Placebo in Combination With Tamoxifen and Goserelin or a Non-steroidal Aromatase Inhibitor (NSAI) and Goserelin for the Treatment of Premenopausal Women With Hormone Receptor Positive, HER2-Negative, Advanced Breast Cancer (MONALEESA-7) |
NCT01997333 | Celidex Therapeutics CDX011-04 | A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients with Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study) |
NCT02132949 | MacroGenics CP-MGAH22-04 | A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Two Prior Anti-HER2 Therapies and Require Systemic Treatment |
Protocol # | Sponsor | Protocol Title |
---|---|---|
NCT02425891 | Hoffmann-La Roche WO29522, 2014-005490-37 | A Study of MPDL3280A in Combination with Nab-Paclitaxel Compared with Placebo with Nab-Paclitaxel for Patients with Previously Untreated Metastatic Triple Negative Breast Cancer |
NCT02000622 | AstraZeneca D0819C00003, 2013-005137-20 | A Phase III, Open Label, Randomized, Controlled, Multi-center Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutations. (OlympiAD) |
NCT01997333 | Celidex Therapeutics CDX011-04 | A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients with Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study) |